Skip to main content
Have a personal or library account? Click to login
Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis Cover

Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis

Radiology and Oncology
Volume 45 (2011): Issue 4 (December 2011)
By: ,  ,  ,  ,  ,  ,   and    
Open Access
|Nov 2011
References

References

  1. Cancer in Slovenia 2007. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia, 2010.
    Search in Google Scholar
  2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer.2005;: 476-87.
    Open DOISearch in Google Scholar
  3. Velenik V, Oblak I, Anderluh F. Quality of life in patients after combined modality treatment of rectal cancer: Report of a prospective phase II study.2008;: 207-14.
    Open DOISearch in Google Scholar
  4. Velenik V. Post-treatment surveillance in colorectal cancer.2010;: 135-41.
    Open DOISearch in Google Scholar
  5. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: colon cancer. V.3.2011 (on line). Avaible:
    Search in Google Scholar
  6. Advanced colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment.2010;: v93-7.
    Open DOISearch in Google Scholar
  7. Kohne CH. How to integrate molecular targeted agents in the continuum of care.2010;: vii134-9.
    Open DOISearch in Google Scholar
  8. Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma.2009;: 1-8.
    Open DOISearch in Google Scholar
  9. Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transducting pathways in colorectal cancer-More than skin deep.2005;: 5374-85.
    Open DOISearch in Google Scholar
  10. Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer.2009;: 2449-60.
    Open DOISearch in Google Scholar
  11. Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.2008;: 4217-9.
    Open DOISearch in Google Scholar
  12. Etienne-Grimaldi M-C, Formento J-L, Francoual M, François E, Formento P, Renée N, et al. K- Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.2008;: 4830-5.
    Open DOISearch in Google Scholar
  13. Ličar A, Cerkovnik P, Ocvirk J, Novaković S. KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment.2010,: 1137-44.
    Open DOISearch in Google Scholar
  14. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with outcome with chemotherapy- refractory metastatic colorectal cancer treated with cetuximab.2010;: 1812-20.
    Open DOISearch in Google Scholar
  15. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild- type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.2008;: 1626-34.
    Open DOISearch in Google Scholar
  16. Roth AD, Tejpar S, Dolorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.2010;:466-74.
    Open DOISearch in Google Scholar
  17. Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Kohne C, et al. The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mCRC receiving first-line treatment with cetuximab or cetuximab plus folfiri. [Abstract].2008;: vi17-8.
    Search in Google Scholar
  18. Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer.2009;: 98-99.
    Open DOISearch in Google Scholar
  19. Ličar A, Cerkovnik P, Novaković S. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer.2010 Jul 20. [Epub ahead of print]
    Open DOISearch in Google Scholar
  20. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effect of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.2010;: 753-62.
    Open DOISearch in Google Scholar
  21. Tejpar S, De Roock W. PIK13CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated With EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium.2009;: 322.
    Open DOISearch in Google Scholar
  22. Lambrechts D, De Roock W, Prenen H, De Schutter J, Jacobs B, Biesmans B, et al. The role of KRAS, BRAF, NRAS and PIK3CA mutations as a marker of resistence of cetuximab in chemorefractory metastatic colorectal cancer. [abstract]2009;172
    Open DOISearch in Google Scholar
  23. Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.2010;: 2396-2402.
    Open DOISearch in Google Scholar
  24. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1).2009;: 228-247.
    Open DOISearch in Google Scholar
  25. Kohne CH, Rougier P, Stroh C, Schlichting M, Bokemeyer C, Van Cutsem E, et al. Cetuximab with chemotherapy as 1st- line treatment for metastatic colorectal cancer: A meta- analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status.2010 [abstract 406].
    Search in Google Scholar
  26. Bookemeyer C, Kohne CH, Rougier P, Stroh C, Schlichting M, Van Cutsem E, et al. Cetuximab with chemotherapy as 1st- line treatment for metastatic colorectal cancer: Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status [abstract].2010;3506
    Open DOISearch in Google Scholar
  27. Tejpar S, Bukemeyer C, Celik I, Schlichting M, Sartorius U, Van Cutsem E, et al. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first- line chemotherapy with or without cetuximab.2011 [abstract 3511].
    Open DOISearch in Google Scholar
  28. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistence to cetuximab + irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.2009;: 715-21.
    Open DOISearch in Google Scholar
  29. Smith G, Bounds R, Wolf H, Steele RJ, Carey FA, Wolf CR, et al. Activating K-ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumoursimplications for personalised cancer medicine.2010;: 1-11.
    Open DOISearch in Google Scholar
  30. Okines A, Del Puerto O, Cunningham D, Chau I, Van Cutsem E, Saltz L, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial.2009;: 1033-8.
    Open DOISearch in Google Scholar
  31. Terrebonne E, Smith D, Becouarn Y, Michel P, Guimbaud M, Fourrier- Reglat A, et al. Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first- line therapy: results of the ETNA cohort study (abstract 3594).2010;15s.
    Open DOISearch in Google Scholar
  32. Ocvirk J, Rebersek M, Boc M. Bevacizumab in first- line therapy of meta-static colorectal cancer: A retrospective comparison of FOLFIRI and XELIRI.2011;: 1777-82.
    Search in Google Scholar
  33. Wong R, Cunningham D, Barbachano Y, et al. A multicentric study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor- risk colorectal liver- only metastases not selected for upfront resection.2011;: 2042-8.
    Open DOISearch in Google Scholar
  34. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.2009;: 1408-17.
    Open DOISearch in Google Scholar
  35. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with or without cetuximab in the first- line treatment of metastatic colorectal cancer.2009;: 663-71.
    Open DOISearch in Google Scholar
  36. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.2010;: 38-47.
    Open DOISearch in Google Scholar
  37. Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, et al. Cetuximab plus chronomodulated irinotecan, 5- fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.2010;: 1-6.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/v10019-011-0039-y | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 285 - 291
Published on: Nov 16, 2011
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
metastatic colorectal cancer,
KRAS,
BRAF,
prognostic factors
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2011 Martina Rebersek, Marko Boc, Petra Cerkovnik, Jernej Benedik, Zvezdana Hlebanja, Neva Volk, Srdjan Novakovic, Janja Ocvirk, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 45 (2011): Issue 4 (December 2011)
Previous article
Next article